Optovue OCT retinal imaging system is available commercially

Optical coherence tomography (OCT) and OCT angiography (OCTA) system developer Optovue (Fremont, CA) has released its AngioVue Retina imaging system commercially, providing retina specialists with a noninvasive, dyeless way to quickly visualize blood flow in the retina, the light-sensitive portion in the back of the eye.

Related: Optovue OCT angiography system is now available commercially in U.S.

AngioVue Retina is configured with essential OCTA and OCT features designed specifically for retinal practices to allow adoption of OCT and OCTA into the clinical workflow with minimal disruption.

The system provides retinal specialists with the ability to quickly visualize the presence or absence of retinal vessels and assess new information about the microvasculature. This information may be integrated with other diagnostic imaging results to form a complete picture of a patient's disease state and their treatment options.

The company has also released its DualTrac Motion Correction for use with both the AngioVue and AngioVue Retina systems, a two-level approach to correcting motion artifacts resulting from patient movement. The first level provides real-time correction for rapid eye movements, blinking, or eye drifting. The second level occurs during imaging post-processing and corrects smaller levels of motion distortion. This combined approach results in robust motion correction for patients who have trouble directing their focus on a central point during an eye exam, which is essential for high-quality OCTA imaging.

Optovue recently received FDA clearance for its AngioVue Imaging System, bringing the significant benefits of noninvasive retinal imaging to patients in the U.S. who suffer from diseases that lead to progressive blindness. In addition to retina applications, the AngioVue System is a comprehensive platform that addresses other ophthalmology applications such as imaging the front of the eye and the optic nerve. The AngioVue System first received regulatory clearance for use outside the U.S. in 2014.

For more information, please visit www.optovue.com.